Glaucoma is the most commonly acquired optic neuropathy. It represents a public health
challenge because it causes an irreversible blindness. Emerging evidence indicates that the …

Ocular drug delivery has many challenges due to the inherent physiology and natural
barriers. Traditionally used eye drops are fairly inefficient with low ocular bioavailability, and …

Glaucoma, a heterogeneous ocular disorder affecting∼ 60 million people worldwide, is
characterized by painless neurodegeneration of retinal ganglion cells (RGCs), resulting in …

Eye is a complex organ with unique anatomy and physiology. The structure of eye can be
divided into two main parts: anterior segment and posterior segment. Due to the special …

Glaucoma is a form of optic neuropathy and a common cause of blindness, affecting over 60
million people worldwide with an expected rise to 80 million by 2020. Successful treatment …

Glaucomatous optic neuropathy is the most commonly acquired optic neuropathy
encountered in clinical practice. It is the second leading cause of blindness globally, after …

Glaucoma and age-related macular degeneration (AMD) are progressive retinal diseases
characterized by increased oxidative stress, inflammation, and mitochondrial dysfunction …

Objectives: To analyse drug development for open-angle glaucoma during the last 20 years.
Methods: Research was performed by referring to clinical trials registered at the International …

To demonstrate a combinatorial drug loaded nanosheet made of alginate and chitosan
which reduces intraocular pressure in a slow and sustained manner depicted by in-vivo …

Glaucoma is an optic neuropathy with multiple known risk factors, including age, race, family
history, and intraocular pressure. Unfortunately, the only currently modifiable risk factor in …